Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
about
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentLestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cellsDistinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosisGene mutations and molecularly targeted therapies in acute myeloid leukemia.Cytotoxic Indolocarbazoles from Actinomadura melliaura ATCC 39691A comprehensive review of glycosylated bacterial natural products.Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.Targeting epigenetic regulations in cancerArtemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trialJAK2 inhibitors in the treatment of myeloproliferative neoplasms.Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.Natural product and natural product derived drugs in clinical trials.Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.The significance of Trk receptors in pancreatic cancer.Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction.miR-216a may inhibit pancreatic tumor growth by targeting JAK2.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives.Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Protein kinase inhibitors for acute leukemia.Marine-derived protein kinase inhibitors for neuroinflammatory diseases.
P2860
Q27027207-DC7621F5-C4EC-479D-BE16-F380FA5B09A6Q28482432-B6E1AB62-5752-4101-98CB-7792AF2D5918Q33413428-D4675281-0E7D-49F8-90F8-7B55068B44FAQ33886243-B43653EB-C2DF-4EF2-A862-1634FFD11DC8Q34647741-91A21BF9-49FA-4BC4-85DC-EC9599494A8BQ35889402-5FD3AC4D-D2B9-411D-802C-F92F640D6C07Q36029831-085BB8F9-D9E8-4408-81A5-A1150AC53A5BQ36214947-FAE794C1-0C48-49C7-B988-EBE19904C466Q36398751-6F89EA94-4BB0-41FC-B2F2-464568B7E0FEQ36916456-005A7268-6882-4452-A95E-E1237D15DA52Q37686415-F3851B5D-4347-458D-B6FF-AE4083934767Q38044736-3F943C01-40F7-4213-920B-F2709D4C28F4Q38210286-9335C69B-1F27-4034-B814-BFF4029B0D52Q38247457-28EC40E8-AC5E-41D5-8F48-AB3132827581Q38493679-BAA653CA-F9A2-4A8B-BB09-56B110E2BF06Q38554422-5D511122-AF70-4A69-83E0-C81EFC22A047Q38715680-4E5AC0F7-2EEF-42C0-B00B-8D8D760DCA88Q38848396-DC444382-277D-4EC5-9BE5-B92997F8EB17Q38856141-346FD72A-4D45-419F-84B6-405312715F8FQ38913785-86616F76-C268-4917-8464-1F7A13CF669CQ38930827-5E9B68BC-A2E6-4A1B-B2E3-61BF70D1ADF5Q39147763-E61F9FD1-6794-46B2-995E-9312B8ED5EFAQ39166795-F3C0FCA5-136F-43B3-A1E5-4E33810C4831Q39166808-1B946CAF-75D4-4248-9E15-E4997CC0A866Q49873905-43D9D0E0-6E35-4B36-9132-FDEFB2123E95Q52565796-527CDF76-6337-479D-88B4-0BD19FC8E43F
P2860
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@ast
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@en
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@nl
type
label
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@ast
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@en
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@nl
prefLabel
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@ast
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@en
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@nl
P2860
P1476
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
@en
P2093
Munira Shabbir
P2860
P304
P356
10.1517/13543781003598862
P407
P577
2010-03-01T00:00:00Z